Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
Open Access
- 27 March 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Abstract
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing in mouse models of TB, inhibits Bcl-2 expression, leading to improved bacterial clearance, reduced tissue necrosis, fibrosis and decreased extrapulmonary bacterial dissemination. Using immunohistochemistry and flow cytometry, we show that navitoclax induces apoptosis in several immune cells, including CD68+ and CD11b+ cells. Finally, positron emission tomography (PET) in live animals using clinically translatable biomarkers for apoptosis (18F-ICMT-11) and fibrosis (18F-FAPI-74), demonstrates that navitoclax significantly increases apoptosis and reduces fibrosis in pulmonary tissues, which are confirmed in postmortem analysis. Our studies suggest that proapoptotic drugs such as navitoclax can potentially improve pulmonary TB treatments, reduce lung damage / fibrosis and may be protective against post-TB lung disease.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01-AI153349, R01-AI145435-A1, R56-AI179012-A1, R01-AI190038)
- U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10-OD030381-A1)
This publication has 64 references indexed in Scilit:
- Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulenceNature Immunology, 2008
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- A guide to murine platelet structure, function, assays, and genetic alterationsJournal of Thrombosis and Haemostasis, 2007
- Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosisHuman Pathology, 2006
- Survival of Virulent Mycobacterium tuberculosis Involves Preventing Apoptosis Induced by Bcl‐2 Upregulation and Release Resulting from Necrosis in J774 MacrophagesMicrobiology and Immunology, 2005
- Ipr1 gene mediates innate immunity to tuberculosisNature, 2005
- Survival of Mycobacterium tuberculosis in Host Macrophages Involves Resistance to Apoptosis Dependent upon Induction of Antiapoptotic Bcl-2 Family Member Mcl-1The Journal of Immunology, 2003
- Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice*Physiological Genomics, 2002
- Mycobacterium tuberculosis Phagosomes Exhibit Altered Calmodulin-Dependent Signal Transduction: Contribution to Inhibition of Phagosome-Lysosome Fusion and Intracellular Survival in Human MacrophagesThe Journal of Immunology, 2001
- Monoclonal Antibody EBM11 (Anti-CD68) Discriminates between Dendritic Cells and Macrophages after Short-Term CultureImmunobiology, 1991